STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Jun-Jul 2026

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

Alex R. Thurman filed a notice to sell 10,000 shares of Glaukos common stock. The shares are planned to be sold on the NYSE through Fidelity Brokerage, with a stated value of $1,600,000.00. They were acquired via a cash stock option exercise dated July 16, 2026. Over the prior three months, Thurman reported three separate 10,000-share sales of Glaukos common stock, with transaction values of $1,400,000.00, $1,500,000.00 and $1,550,000.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
other
-
Rhea-AI Summary

Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman exercised stock options for 10,000 shares of Common Stock at $38.68 per share and, on the same date, sold 10,000 shares at $155.00 per share in an open-market transaction, all under a Rule 10b5-1 trading plan.

After these transactions, he holds 43,681 shares directly, including 5,230 restricted stock units that have not yet vested or been delivered, and 10,000 stock options with a $38.68 exercise price expiring on October 6, 2026, which vest over four years from the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
insider
-
Rhea-AI Summary

Glaukos Corporation notice reports an intended sale of 10,000 shares of Common Stock on 07/09/2026 by Fidelity Brokerage Services LLC, reflecting a reported aggregate value of $1,550,000.00. The filing also records a stock option exercise tied to the same 10,000 shares with cash consideration on 07/09/2026.

The excerpt lists prior Rule 144 dispositions by Alex R. Thurman: 10,000 shares on 04/30/2026 for $1,400,000.00 and 10,000 shares on 07/06/2026 for $1,500,000.00. Shares outstanding are shown as 58,733,911 as of 07/09/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
other
Rhea-AI Summary

Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman reported an exercise-and-sale transaction in company stock. On July 6, 2026, he exercised stock options for 10,000 shares of common stock at $38.68 per share and, on the same date, sold 10,000 shares of common stock in an open-market transaction at $150.00 per share. After these transactions, he directly holds 43,681 shares of Glaukos common stock, in addition to 5,230 restricted stock units that are unvested. Both the sale and the option exercise were carried out under a Rule 10b5-1 trading plan adopted on December 15, 2025, indicating they were pre-arranged rather than opportunistic market trades.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
insider
-
Rhea-AI Summary

Glaukos Corp chief development officer Tomas Navratil reported a small open-market sale of company stock. On July 1, he sold 716 shares of Glaukos common stock at an average price of $139.06 per share in an open-market transaction.

After the sale, Navratil directly holds 87,634 shares of Glaukos common stock, so the transaction represents a minor portion of his overall stake. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance. His holdings also include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
insider
-
Rhea-AI Summary

Glaukos Corp. disclosure shows a reported sale transaction involving 10,000 shares of Common Stock tied to a Stock Option Exercise. The filing lists a broker/dealer Fidelity Brokerage Services LLC and dates including 04/30/2026 for a past sale and 07/06/2026 as a securities-to-be-sold date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
other
Rhea-AI Summary

GLAUKOS Corp (GKOS) officer Tomas Navratil reports a proposed sale of 716 common shares, with an approximate sale date of July 1, 2026, and an aggregate market value of $99,566.96. The notice lists March 12, 2026, as the Rule 10b5-1 plan adoption or instruction date. The shares came from restricted stock vesting on March 24, 2025, as compensation. During the prior three months, Navratil reported sales of 2,093 shares for gross proceeds of $246,177.94 on April 10, 2026, and 1,537 shares for gross proceeds of $200,855.16 on June 16, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
other
-
Rhea-AI Summary

Glaukos Corp chairman and CEO Thomas William Burns reported updated holdings of the company’s common stock, mainly through several family and charitable trusts. The filing lists indirect positions including 100,000 shares through the Janet M. Burns Irrevocable Trust and 1,141,593 shares through the Burns Family Trust.

The only actual share movement was a tax-withholding disposition of 4,059 directly held shares at $142.57 per share to satisfy tax obligations upon vesting and delivery of restricted stock units granted on March 18, 2021. After this, he directly holds 68,967 shares, and his position also includes 56,382 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,056 shares of common stock to cover his tax withholding obligations at $142.57 per share.

After this withholding, Gilliam directly holds 72,363 shares of common stock. This position includes 41,983 restricted stock units that have been granted but have not yet vested or been delivered, reflecting ongoing equity-based compensation rather than an open-market sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp Chief Development Officer Tomas Navratil reported a small share disposition related to tax withholding, not a market sale. On this Form 4, 483 shares of common stock were withheld by the company at $142.57 per share to satisfy tax obligations upon vesting of restricted stock units granted on March 18, 2021.

After this tax-withholding event, Navratil directly holds 88,350 shares of GLAUKOS common stock, which the filing notes include 38,817 restricted stock units that have not yet vested or been delivered. This filing reflects a routine compensation and tax event rather than an open-market trade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
insider

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.